Video

The Current Challenges Facing Cell Therapy Manufacturing

Source: Invetech

During our second Cell & Gene Live – Can Innovation Drive Down Cell Therapy Manufacturing Costs? – panelists Dr. Mark Gilbert, SVP of R&D of Acepodia; Thomas Lequertier, Head of Cell Therapy Manufacturing Unit of Celyad Oncology; and Luděk Sojka, Ph.D., Chief Technology Officer of SOTIO discussed how both allogeneic and autologous therapies alike are affected by the high cost of manufacturing. Indeed, the high cost of producing new cell therapies, particularly gene-edited cell therapies such as CAR T-cell therapy, for example, are notoriously expensive. Advancements in manufacturing are driving costs down, but not at the required pace. The complex manufacturing process that these biological treatments require means that their price is currently at a premium. 

In this webinar segment, Dr. Mark Gilbert, Thomas Lequertier, and Luděk Sojka explain the many current challenges associated with cell therapy manufacturing.

access the Video!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene